Export NOC for r-DNA drugs is a significant change in regulations that could benefit the pharmaceutical industry.
biotech
Avidity acquisition news: The Worst Phase 3 Setback Revealed
Avidity acquisition news reveals the latest Phase 3 setback for Novartis’ dystrophy drug, raising concerns in the pharma industry.